New and updated preclinical data presented at the European Society of Gene and Cell Therapy 29th Congress in Edinburgh, Scotland, by: Cellectis, Chameleon, Gentibio, M6P, Vor Biopharma, Voyager Therapeutics.

Additional early-stage research and drug discovery news in brief, from: Codiak, Dyne, Halberd.

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to epidermal growth factor receptor (EGFR)-binding moiety through linker reported to be useful for the treatment of cancer.

Betta Pharmaceuticals Co. Ltd. has synthesized GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Chiesi Farmaceutici SpA has identified tyrosine-protein kinase JAK1 and/or JAK2 and/or JAK3 and/or TYK2 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.

Humanwell Healthcare (Group) Co. Ltd. has disclosed G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, autoimmune and metabolic diseases, among others.

Nutshell Biotech (Shanghai) Co. Ltd. has discovered fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer.

Dicot AB reports that LIB-01 has shown a...

Nimbus Therapeutics LLC has entered into a...